Preliminary analysis shows one complete response (CR) and two partial responses
Median progression-free survival (PFS) for Part A was 5.5 months (n=9), versus thehistorical control of 3.4 months,
Growing body of data provides strong evidence that Cantrixil is clinically active in thisvery late-stage patient population
Safety profile consistent with prior experience: most common adverse events weregastrointestinal in nature and low-grade
Australian lead investigator, Associate Professor Jermaine Coward, commented
“despite recent progress in ovarian cancer, there remains an urgent need for new therapies.
The Cantrixil phase I study was conducted in a very late-stage patient population, with few effective treatment options.
In that context, my colleagues and I consider these data to be extremely promising.”
Cantrixil has been able to shrink tumours and delay disease progression, demonstrating a clinically meaningful benefit
- Forums
- ASX - By Stock
- KZA
- Ann: Cantrixil last patient visit
Ann: Cantrixil last patient visit, page-3
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review